Target Protein Ligand Discovery and Screening

* Please be kindly noted that our services and products can only be used for research to organizations or companies and not intended for any clinical or individuals.

Every degrader program begins with the same practical question: do you have a ligand for your target protein that is good enough to become a warhead? Many disease-relevant targets have no known binders, only weak inhibitors, or structures with no obvious entry point for a linker. Target protein ligand discovery and screening is the discipline that turns a protein of interest into a set of validated, attachable starting points on which the rest of a degradation project can be built.

BOC Sciences provides target protein ligand discovery and screening services for targeted protein degradation, covering target and binding-site assessment, library selection, computational and experimental screening, hit validation, affinity profiling, and PROTAC-oriented ligand optimization. We integrate structure-based modeling, biochemical and biophysical assays, and medicinal chemistry so that every hit we deliver is judged not only on affinity, but on whether it can carry a linker and support productive ternary complex formation.

Request a Consultation Explore Services
Services

BOC Sciences Target Protein Ligand Discovery and Screening Services for TPD Development

BOC Sciences runs ligand discovery as a connected workflow rather than a set of isolated experiments. Our target protein services supply the well-characterized recombinant protein that every reliable screen depends on, and our broader ligand design for target protein capabilities carry validated hits forward into full degrader design. The service modules below can be combined into a single campaign or engaged individually, depending on where your program stands.

Gene Therapy

Target Protein and Binding-Site Assessment

We help determine whether your target protein can support ligand discovery and degrader assembly, through:

  • Target feasibility service: evaluation of domain architecture, ligand history, cellular localization, and degradation potential, informed by our target degradability assessment for TPD development.
  • Binding-site ligandability service: identification of ligandable pockets, including allosteric and transiently open sites, built on our binding pocket analysis for TPD development.
  • Protein readiness service: construct design and recombinant production so that screening starts from functional, well-characterized target material.
Gene Therapy

Ligand Library Selection and Screening Strategy

BOC Sciences matches compound sources and methods to each target before any screen is run, using:

  • Library selection service: target-class-matched compound sets selected from our screening library according to pocket properties and program goals.
  • Warhead-oriented design service: candidate sets weighted toward degrader-compatible scaffolds with defined exit vectors, drawing on our warhead library.
  • Campaign planning service: a written screening strategy that sequences computational and experimental tracks and defines decision gates between them.
Gene Therapy

Computational Screening and Hit Prioritization

BOC Sciences reduces large chemical space to a manageable, high-quality candidate list through:

  • Virtual screening service: docking and pharmacophore-based searches across curated compound sets, delivered through our virtual screening capabilities.
  • Structure preparation service: pocket refinement and homology or predicted models when experimental structures are incomplete, supported by our molecular docking for protein-ligand platform.
  • Hit prioritization service: multi-parameter ranking on predicted affinity, binding pose, novelty, and linker-attachment potential, so only synthesis-worthy candidates move forward.
Gene Therapy

Experimental Ligand Screening and Hit Identification

BOC Sciences generates real binding data for every prioritized candidate set through:

  • Biochemical screening service: high-throughput assays in biochemical and cell-lysate formats to detect genuine target engagement across large candidate sets.
  • Small-molecule discovery service: identification and triage of target binders suitable for warhead conversion, aligned with our small molecule target protein ligand services.
  • Peptide discovery service: screening of peptide candidates for targets without small-molecule entry points, connected to our peptide ligand for target protein capabilities.
Gene Therapy

Hit Validation and Binding Characterization

BOC Sciences separates real ligands from assay noise before chemistry resources are committed, using:

  • Orthogonal confirmation service: dose-response, competition, and counter-screening experiments that exclude aggregators, pan-assay artifacts, and false positives.
  • Affinity profiling service: quantitative KD determination and kinetic analysis through our binding affinity measurement capabilities.
  • Target-engagement confirmation service: biophysical and cellular engagement studies drawn from our target ligand binding assays for TPD development.
Gene Therapy

Ligand Expansion and PROTAC-Oriented Optimization

BOC Sciences prepares each validated hit for degrader assembly through:

  • SAR expansion service: analog design and synthesis to improve affinity, selectivity, and physicochemical behavior around the confirmed binding motif.
  • Exit-vector mapping service: identification of solvent-exposed attachment points that preserve binding geometry when the linker is installed.
  • Linker compatibility service: assessment of how attachment position and geometry survive conjugation, coordinated with our linker binding site selection and design services.
Screening Technologies

Screening Technologies for Target Protein Ligand Discovery

No single screening method fits every target protein. BOC Sciences assembles a technology package for each campaign based on pocket properties, protein behavior, and the exit-vector requirements of the final degrader, rather than defaulting to one preferred platform.

Structure-Based and Ligand-Based Virtual Screening

Computational screening lets us survey chemical space before a single wet-lab experiment is scheduled. BOC Sciences combines complementary computational approaches, including:

  • Structure-based methods: molecular docking, pharmacophore modeling, and pocket-focused searches applied to crystal, cryo-EM, or predicted target structures.
  • Ligand-based methods: similarity searching and SAR extrapolation from known binder series when experimental structures are limited.
  • Prioritization layers: rescoring of docked poses with interaction fingerprints, strain analysis, and synthetic-accessibility filters to protect downstream chemistry budgets.

High-Throughput Biochemical and Functional Screening

For targets with tractable assay formats, BOC Sciences runs experimental screening at scale to capture binding behavior that computation alone cannot predict. Our high-throughput capabilities include:

  • Biochemical assay formats: fluorescence, TR-FRET, luminescence, and absorbance readouts adapted to the catalytic or binding behavior of the target.
  • Assay development and qualification: optimization of protein construct, substrate, and detection conditions before library deployment, so hits reflect biology rather than assay artifacts.
  • Hit triage pipeline: automated data review with concentration-response confirmation to move only reproducible candidates forward.

Fragment-Based Screening

Fragment screening is our default route for targets with shallow, flexible, or poorly characterized binding sites. BOC Sciences applies fragment-based discovery through:

  • Sensitive detection formats: NMR, SPR, thermal shift, and ligand-observed methods tuned to detect weak millimolar-range binding reliably.
  • Fragment-to-warhead elaboration: structure-guided fragment growing and merging that raise affinity while preserving the ligand efficiency needed for a degrader-sized molecule.
  • Exit-vector-aware design: evaluation of each growing direction against future linker attachment, so elaborated fragments do not lose the property that matters most for PROTAC assembly.

Biophysical Binding Assays

Biophysical measurements anchor every hit-validation decision in our campaigns. BOC Sciences characterizes target-ligand binding through:

  • Kinetic and affinity measurement: SPR and related label-free formats providing association rate, dissociation rate, and KD values for candidate ranking.
  • Thermodynamic profiling: ITC-based characterization of binding drivers, useful for distinguishing enthalpy-driven specific binding from entropy-driven nonspecific interaction.
  • Complementary confirmation: thermal shift, MST, and NMR chemical-shift mapping used as orthogonal checks on binding mode and site assignment.
Ligand Classes

Target Protein Ligand Classes We Support for Development

Ligand discovery strategy changes with the target class. BOC Sciences adapts pocket analysis, library composition, and screening formats to the structural and biological behavior of each protein family rather than running one generic campaign for every target.

Gene Therapy

Kinases and Enzyme Targets

Kinases and enzymes often carry rich ligand history but need careful selectivity management for degrader use. BOC Sciences evaluates existing inhibitors, hinge-binding motifs, and allosteric pockets to identify warhead starting points with room for linker installation. Known active scaffolds can be converted into degradation-ready warheads through our known ligand-derived warhead discovery services, with selectivity reviewed across closely related family members.

Gene Therapy

Transcription Factors and Epigenetic Regulators

Transcription factors and epigenetic readers frequently lack deep classical pockets, so discovery depends on surface clefts, bromodomain-like cavities, and induced-fit behavior. BOC Sciences combines pocket prediction, fragment screening, and conformational analysis to locate ligandable regions on these targets, then prioritizes candidates whose binding leaves a solvent-exposed vector for linker attachment rather than maximizing affinity alone.

Gene Therapy

Protein-Protein Interaction and Scaffold Proteins

Scaffold proteins and signaling hubs act through large, shallow interfaces that resist conventional inhibitor design. BOC Sciences maps hot spots across these interfaces, screens fragment and library sets against the most ligandable hot-spot clusters, and evaluates whether discovered binders can support productive ternary complex geometry. For targets without any small-molecule history, peptide candidates provide an alternative route to target engagement.

Gene Therapy

Mutant and Isoform-Selective Target Proteins

Mutant and isoform-selective targets demand ligands that discriminate between proteins differing by a single residue or domain. BOC Sciences compares wild-type and variant structures, uses molecular dynamics simulation to expose mutation-specific pocket features, and designs or screens candidate ligands against both forms so that selectivity is measured, not assumed, before the ligand enters degrader design.

Need Ligands for a Challenging Target Protein?

Whether your target has no known binders, weak inhibitors, or a binding site that resists conventional screening, BOC Sciences can design a ligand discovery campaign around its structural and biological reality. Share your target, existing data, and program goals with our team.

Discuss Your Target

Workflow

Our Workflow for Target Protein Ligand Discovery and Screening

01

Project Consultation and Requirement Assessment

We review your target protein, program stage, existing ligand and structural data, and the degradation objective behind the project. This defines what a successful ligand must deliver: affinity, selectivity, exit vectors, and compatibility with the degrader architecture you intend to build.

02

Target Analysis and Screening Strategy Development

We analyze ligandability, select compound libraries, and design the campaign sequence, deciding which targets go virtual first, which need fragment methods, and which warrant both. Every strategy is documented with go/no-go criteria before screening begins.

03

Ligand Screening and Hit Identification

Computational and experimental tracks run in parallel, with computational lists feeding assay design and assay results refining the computational models. Confirmed hits are ranked on binding quality, novelty, and attachment potential.

04

Hit Validation and PROTAC Compatibility Evaluation

Validated ligands are delivered with affinity data, binding-mode evidence, and exit-vector recommendations, then carry forward into PROTAC design services for linker assembly, E3 ligand pairing, and ternary complex evaluation.

Ready to Launch a Ligand Discovery Campaign?

BOC Sciences can take your project from target assessment through validated, degrader-ready ligands within a single coordinated workflow. Tell us where your program stands, and we will propose a screening strategy matched to your target and timeline.

Start Your Campaign

Troubleshooting

Challenges We Solve in Target Protein Ligand Discovery Projects

Ligand discovery for degradation programs fails in predictable ways. BOC Sciences addresses the most common failure modes with structural analysis, assay design, and structure-guided optimization.

No Known Ligands or Limited Structural Information

Many degrader targets have no published binders and incomplete or predicted-only structures, leaving teams without a clear starting point. BOC Sciences combines pocket prediction, molecular dynamics simulation to reveal cryptic and transient binding sites, and sensitive fragment-based screening to generate first-generation ligands where conventional campaigns would find nothing.

Weak Binding Signals and Screening Artifacts

Screening campaigns frequently return hits that are aggregators, redox cyclers, or assay-platform artifacts rather than true ligands. BOC Sciences builds counter-screening and orthogonal confirmation into every campaign, requiring hits to reproduce across independent formats and show concentration-dependent behavior before any chemistry investment is made.

Poor Selectivity Among Related Proteins

Ligands identified against one family member often bind its close relatives equally well, which undermines both functional studies and degradation selectivity. BOC Sciences profiles validated hits against related family members, traces selectivity to specific pocket residues, and directs SAR expansion toward interactions that the intended target, and only the intended target, provides.

Loss of Target Binding After Linker Attachment

A strong ligand can lose most of its affinity once the linker occupies an attachment point that was secretly part of the binding pharmacophore. BOC Sciences maps exit vectors before conjugation, evaluates binding after linker installation, and adjusts attachment position or linker design with our linker design and optimization services so that target engagement survives degrader assembly.

Facing Challenges in Target Protein Ligand Discovery?

Whether you are struggling with a target that has no known ligands, untrustworthy screening hits, poor selectivity, or ligands that fail after linker attachment, BOC Sciences can diagnose the problem and redirect your discovery campaign.

Discuss Your Challenges

Why Us

Why Choose BOC Sciences for Target Protein Ligand Discovery and Screening?

Integrated Computational and Experimental Screening Capabilities

Virtual screening, biochemical assays, and biophysical characterization run inside one team, so computational hypotheses are tested quickly and assay feedback continuously improves the models. The result is a shorter path from an empty target page to a validated ligand list.

Target-Specific Screening Strategies and Library Resources

Library composition, assay format, and screening method are chosen for the pocket and target class in front of us, not pulled from a fixed pipeline. Kinases, transcription factors, scaffold proteins, and mutant targets each receive a campaign designed around their structural behavior.

Orthogonal Hit Validation and Binding Characterization

Every recommended ligand is supported by affinity, kinetics, and binding-mode evidence from independent methods, so the hits you receive have already survived the artifact filters that consume so many internal screening budgets.

PROTAC-Oriented Ligand Optimization Capabilities

Ligands are expanded and optimized with exit vectors, linker geometry, and ternary complex feasibility in view from the first design cycle, so what we hand over is not merely a binder but a warhead candidate ready for degrader assembly and degradation testing.

Frequently Asked Questions (FAQ)

Frequently Asked Questions

Still have questions?

Contact Us

Target protein ligand discovery generally combines computational and experimental screening to identify potential binders efficiently. Common approaches include structure-based virtual screening, ligand-based similarity searching, high-throughput screening, and fragment-based screening. When a reliable protein structure is available, molecular docking and pharmacophore modeling can help prioritize compounds with favorable binding interactions. For targets with limited ligand information, fragment screening and biophysical methods may provide alternative starting points. Initial candidates should then undergo experimental validation to confirm direct target engagement, characterize their binding properties, and determine whether they are suitable for further ligand optimization.

The most appropriate screening method depends on protein structure availability, binding-site characteristics, known ligand information, and accessible experimental readouts. For targets with reliable three-dimensional structures, molecular docking and structure-based virtual screening can help prioritize potential binders. When known ligands are available, similarity searching and pharmacophore screening provide additional discovery options. For targets with limited ligand information, high-throughput or fragment-based screening may be useful. Biophysical techniques such as SPR, BLI, MST, and ITC can provide complementary evidence of direct binding. Combining multiple methods can improve hit identification and validation.

Initial screening hits do not necessarily represent genuine target binders, as assay interference, compound aggregation, and nonspecific interactions may produce false-positive signals. Orthogonal validation is therefore important. SPR and BLI can characterize binding kinetics, while MST and ITC provide complementary information about protein-ligand interactions. NMR can also support the investigation of molecular binding. Additional concentration-dependent experiments, competitive binding assays, and counter-screening help distinguish specific interactions from nonspecific effects. Where appropriate, structural analysis can further identify the binding location, molecular orientation, and key interacting residues, providing a stronger basis for subsequent ligand optimization.

A suitable target ligand for PROTAC development should provide reliable target recognition while offering structural features compatible with chemical modification. Important considerations include binding affinity, target selectivity, and the ligand's binding mode. An accessible region for linker attachment is also desirable because modification at an unsuitable position may disrupt key protein-ligand interactions. Furthermore, the ligand should be evaluated in the context of the complete degrader architecture, since linker attachment and E3 ligase recruitment can influence ternary complex formation. Therefore, selecting a PROTAC warhead requires more than identifying a high-affinity binder; structural compatibility and potential degradation performance should also be considered.

For target proteins without established small-molecule binders, BOC Sciences can begin with available protein structures, sequence information, and relevant research data to assess potential binding sites and ligandability. Depending on the target, we can integrate protein structure modeling, binding-pocket analysis, virtual screening, compound library screening, and fragment-based approaches to identify candidate ligands. When initial hits are obtained, complementary biophysical binding assays and structural characterization can help confirm target engagement and investigate binding modes. We can also evaluate chemical modification opportunities, linker attachment positions, and PROTAC compatibility to support the progression from initial ligand discovery to degrader-oriented development.

* PROTAC® is a registered trademark of Arvinas Operations, Inc., and is used under license.

BOC Sciences Support

Please contact us with any specific requirements and we will get back to you as soon as possible.

  • Verification code
Inquiry Basket